Security
Tyra Biosciences, Inc. Common Stock · TYRA
TYRANASDAQCommon stockCurrentCIK 1863127Updated Oct 28, 2026
TYRA price & chart
Loading TradingView…
NASDAQ:TYRA on TradingView ↗About the company
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help TYRA design and predict which candidates may demonstrate the highest potency, selectivity and tolerability in the clinic. TYRA’s expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA’s lead precision candidate stemming from SNÅP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG UTUC, IR NMIBC and ACH. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4- driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, California.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA ↗
Seeking Alpha
Tyra Biosciences prices $400 million equity offering to fund dabogratinib development and other programs ↗
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript ↗
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow ↗
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 301,851,000Source | 380,592,000Source | 383,362,000Source | 321,499,000Source | 392,461,000Source | 412,040,000Source | 343,476,000Source | 404,741,000Source | 282,609,000Source | 363,558,000Source | 225,857,000Source | 266,181,000Source |
| Property, Plant and Equipment, NetUSD | 1,346,000Source | 1,789,000Source | 1,173,000Source | 1,413,000Source | 1,898,000Source | 1,215,000Source | 1,522,000Source | 1,593,000Source | 1,314,000Source | 1,651,000Source | 1,628,000Source | 1,077,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 61,951,000Source | 103,892,000Source | 73,835,000Source | 98,490,000Source | 99,490,000Source | 84,955,000Source | 100,721,000Source | 254,366,000Source | 77,387,000Source | 91,966,000Source | 58,006,000Source | 251,213,000Source |
| Assets, CurrentUSD | 281,216,000Source | 365,611,000Source | 366,966,000Source | 302,155,000Source | 378,574,000Source | 394,613,000Source | 324,566,000Source | 390,778,000Source | 265,450,000Source | 347,463,000Source | 211,671,000Source | 257,288,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,292,000Source | 5,481,000Source | 13,022,000Source | 5,884,000Source | 4,778,000Source | 11,147,000Source | 5,623,000Source | 8,316,000Source | 9,447,000Source | 6,022,000Source | 8,202,000Source | 6,075,000Source |
| Other Assets, NoncurrentUSD | 12,590,000Source | 6,006,000Source | 9,028,000Source | 11,109,000Source | 4,693,000Source | 9,885,000Source | 10,442,000Source | 4,958,000Source | 9,272,000Source | 7,376,000Source | 5,032,000Source | 4,350,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 21,342,000Source | 18,304,000Source | 29,698,000Source | 19,352,000Source | 16,418,000Source | 24,465,000Source | 19,942,000Source | 14,862,000Source | 23,432,000Source | 20,407,000Source | 21,595,000Source | 8,352,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 4,000Source | 4,000Source |
| Retained Earnings (Accumulated Deficit)USD | -337,424,000Source | -225,740,000Source | -456,121,000Source | -307,556,000Source | -201,724,000Source | -410,563,000Source | -279,458,000Source | -183,022,000Source | -371,258,000Source | -251,311,000Source | -164,830,000Source | -95,696,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 442,000Source | 1,752,000Source | -580,000Source | 436,000Source | -184,000Source | 107,000Source | 688,000Source | -6,000Source | 393,000Source | 770,000Source | 381,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 280,509,000Source | 362,288,000Source | 353,664,000Source | 302,147,000Source | 376,043,000Source | 387,575,000Source | 323,534,000Source | 389,879,000Source | 259,177,000Source | 343,151,000Source | 204,262,000Source | 257,829,000Source |
| Additional Paid in Capital, Common StockUSD | 617,486,000Source | 586,271,000Source | 810,359,000Source | 609,262,000Source | 577,946,000Source | 798,025,000Source | 602,299,000Source | 572,902,000Source | 630,037,000Source | 593,687,000Source | 368,707,000Source | 353,521,000Source |
| Liabilities and EquityUSD | 301,851,000Source | 380,592,000Source | 383,362,000Source | 321,499,000Source | 392,461,000Source | 412,040,000Source | 343,476,000Source | 404,741,000Source | 282,609,000Source | 363,558,000Source | 225,857,000Source | 266,181,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,879,000Source | 12,373,000Source | 24,620,000Source | 13,770,000Source | 10,382,000Source | 19,256,000Source | 14,246,000Source | 8,716,000Source | 18,094,000Source | 14,594,000Source | 15,333,000Source | 5,701,000Source |
| Operating Lease, Liability, CurrentUSD | 456,000Source | 398,000Source | 504,000Source | 441,000Source | 383,000Source | 488,000Source | 426,000Source | 370,000Source | 472,000Source | 412,000Source | 280,000Source | 140,000Source |
| Accounts Payable, CurrentUSD | 1,991,000Source | 1,165,000Source | 2,334,000Source | 2,245,000Source | 1,577,000Source | 3,642,000Source | 2,500,000Source | 2,879,000Source | 1,178,000Source | 590,000Source | 4,662,000Source | 1,145,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,463,000Source | 5,920,000Source | 5,078,000Source | 5,582,000Source | 6,016,000Source | 5,209,000Source | 5,696,000Source | 6,117,000Source | 5,338,000Source | 5,810,000Source | 6,216,000Source | 2,482,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 11,000Source | — | 0Source | 20,000Source | — | 0Source | 29,000Source | 0Source | 3,000Source | 46,000Source | 169,000Source |
| Operating Lease, Right-of-Use Asset | — | — | —Source | — | — | — | — | — | — | — | — | — |
| Restricted Cash and Investments, Current | — | — | —Source | —Source | — | —Source | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 138,000Source | 143,000Source | 546,000Source | 519,000Source | 353,000Source | 296,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 7,847,000Source | 6,422,000Source | 28,006,000Source | 22,801,000Source | 13,525,000Source | 10,588,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -32,571,000Source | -25,458,000Source | -95,142,000Source | -69,774,000Source | -50,139,000Source | -50,285,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -120,244,000Source | 32,026,000Source | 72,463,000Source | -98,403,000Source | -144,605,000Source | -559,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 88,000Source | 14,000Source | 141,000Source | 664,000Source | 770,000Source | 559,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 160,383,000Source | 2,187,000Source | 8,100,000Source | 202,137,000Source | 1,537,000Source | 632,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 7,568,000Source | 8,755,000Source | -14,579,000Source | 33,960,000Source | -193,207,000Source | -50,212,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 62,951,000Source | 104,892,000Source | 74,835,000Source | 99,490,000Source | 85,955,000Source | 101,721,000Source | 78,387,000Source | 92,966,000Source | 59,006,000Source | 252,213,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,577,000Source | 7,573,000Source | 10,232,000Source | 6,380,000Source | 7,847,000Source | 6,422,000Source | 28,006,000Source | 22,801,000Source | 13,525,000Source | 10,588,000Source |
| DepreciationUSD | — | — | — | 100,000Source | — | — | — | 100,000Source | — | 500,000Source | 400,000Source | 296,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | -4,000Source | -3,000Source |
| General and Administrative ExpenseUSD | — | — | 7,475,000Source | 5,907,000Source | 9,806,000Source | 7,143,000Source | 8,528,000Source | 6,886,000Source | 29,834,000Source | 24,100,000Source | 17,427,000Source | 15,919,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 2,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,868,000Source | -24,016,000Source | -45,558,000Source | -28,098,000Source | -39,305,000Source | -28,147,000Source | -119,947,000Source | -86,481,000Source | -69,134,000Source | -55,325,000Source |
| Nonoperating Income (Expense)USD | — | — | 3,076,000Source | 4,588,000Source | 3,445,000Source | 3,354,000Source | 2,693,000Source | 3,703,000Source | 12,815,000Source | 17,696,000Source | 10,811,000Source | 3,602,000Source |
| Operating ExpensesUSD | — | — | 32,944,000Source | 28,604,000Source | 49,003,000Source | 31,452,000Source | 41,998,000Source | 31,850,000Source | 132,762,000Source | 104,177,000Source | 79,945,000Source | 58,927,000Source |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Restricted Cash and Investments, Current | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -32,944,000Source | -28,604,000Source | -49,003,000Source | -31,452,000Source | -41,998,000Source | -31,850,000Source | -132,762,000Source | -104,177,000Source | -79,945,000Source | -58,927,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 2,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -29,868,000Source | -24,016,000Source | -45,558,000Source | -28,098,000Source | -39,305,000Source | -28,147,000Source | -119,947,000Source | -86,481,000Source | -69,134,000Source | -55,325,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.5Source | -0.41Source | -0.69Source | -0.47Source | -0.64Source | -0.47Source | -2.01Source | -1.51Source | -1.62Source | -1.32Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.5Source | -0.41Source | -0.69Source | -0.47Source | -0.64Source | -0.47Source | -2.01Source | -1.51Source | -1.62Source | -1.32Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 59,670,757Source | 58,874,497Source | 65,991,171Source | 59,550,771Source | 61,746,050Source | 59,336,550Source | 59,602,328Source | 57,217,746Source | 42,704,876Source | 41,883,904Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 59,670,757Source | 58,874,497Source | 65,991,171Source | 59,550,771Source | 61,746,050Source | 59,336,550Source | 59,602,328Source | 57,217,746Source | 42,704,876Source | 41,883,904Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 7,475,000Source | 5,907,000Source | 9,806,000Source | 7,143,000Source | 8,528,000Source | 6,886,000Source | 29,834,000Source | 24,100,000Source | 17,427,000Source | 15,919,000Source |
| Interest and Other IncomeUSD | — | — | 3,076,000Source | 4,588,000Source | 3,445,000Source | 3,354,000Source | 2,693,000Source | 3,703,000Source | 12,815,000Source | 17,696,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 3,076,000Source | 4,588,000Source | 3,445,000Source | 3,354,000Source | 2,693,000Source | 3,703,000Source | 12,815,000Source | 17,696,000Source | 10,811,000Source | 3,602,000Source |
| Operating ExpensesUSD | — | — | 32,944,000Source | 28,604,000Source | 49,003,000Source | 31,452,000Source | 41,998,000Source | 31,850,000Source | 132,762,000Source | 104,177,000Source | 79,945,000Source | 58,927,000Source |
| Research and Development ExpenseUSD | — | — | 25,469,000Source | 22,697,000Source | 39,197,000Source | 24,309,000Source | 33,470,000Source | 24,964,000Source | 102,928,000Source | 80,077,000Source | 62,518,000Source | 43,008,000Source |
Offerings
Registration 333-298911
Filing attachments
tm2625388d1_ex99-1.htm · SCHEDULE 13G · 2026-09-17
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Shares, par value $0.0001 per share, of Tyra Biosciences, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby ex…
Read attachment ↗d102025dex41.htm · 8-K · 2026-09-15
EX-4.1 3 d102025dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK TYRA BIOSCIENCES, INC. Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 Tyra Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the ter…
Read attachment ↗d102025dex991.htm · 8-K · 2026-09-15
EX-99.1 5 d102025dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants CARLSBAD, Calif., September 14, 2026 - Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the pricing of an underwritten offering of 9,079,000 shares…
Read attachment ↗d49930dex45.htm · S-3ASR · 2026-09-14
Exhibit 4.5 TYRA BIOSCIENCES, INC. INDENTURE Dated as of ___________, 20___ [____________] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2…
Read attachment ↗tyra-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 tyra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalen…
Read attachment ↗tyra-ex99_1.htm · 8-K · 2026-05-13
EX-99.1 2 tyra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - Advanced “dabogratinib 3x3” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort i…
Read attachment ↗